Type
Internal restructuring
Country
Germany
Region
Location of affected unit(s)
Tübingen, Wiesbaden
Sector
Professional Services
Scientific, Architectural And Engineering Technical Activities
Scientific Research And Development
72.11 - Research And Experimental Development On Biotechnology

150 jobs
Number of planned job losses
Job loss
Announcement Date
16 March 2024
Employment effect (start)
16 March 2024
Foreseen end date

Description

The German biotech company Curevac, headquartered in Tübingen, has announced 150 job cuts at its sites in Tübingen and Wiesbaden.

Curevac explains the job cuts by saying that the organisational structures are now to be tailored to the current scope of business and the broader sales process. The jobs affected are mainly in operations, which primarily corresponds to clinical production. The organisational structures were originally optimised and expanded for the pandemic-related provision of a Covid-19 vaccine Curevac 2020-DE. Most of the jobs are to be cut at the headquarters in Tübingen and a few at the site in Wiesbaden. The redundancies are to be implemented through voluntary redundancy agreements and severance payments. The programme has been launched and will run over the coming weeks.

Curevac is a global biopharmaceutical company specialising in mRNA technology. The company employs more than 1,100 people at sites in Germany, the Netherlands, Belgium, Switzerland and the USA.


Sources

Citation

Eurofound (2024), Curevac, Internal restructuring in Germany, factsheet number 201020, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/201020.